MedTrace Logo

Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006

NCT02008513 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2015-06-24

No results posted yet for this study

Summary

This is a follow-up study to assess safety and clinical activity of continued AFFITOPE® AD02 vaccinations in patients with Alzheimer's disease. Patients, who have already participated in AFF006 will be involved in 27 study sites in Europe. Duration of patient's participation in the clinical trial is 19 months.

Conditions

  • Alzheimer´s Disease

Interventions

BIOLOGICAL

AFFITOPE® AD02

BIOLOGICAL

Placebo

Sponsors & Collaborators

  • Affiris AG

    lead INDUSTRY

Principal Investigators

  • Bruno Dubois, Prof. · Centre des Maladies Cognitives et Comportementales, Federation des maladies du systeme nerveux, Hoptial de la Salpetriere, Pavillon Paul Castaignes (Sous-sol), 47-83 Bd de l'Hopital, 75651 Paris Cedex 13

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • Austria
  • Croatia
  • Czechia
  • France
  • Germany
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02008513 on ClinicalTrials.gov